SCHEMBL4080677

SCHEMBL4080677

N#Cc1ccc(-c2csc(Nc3ccccc3O)n2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.70
VCP P55072 3/20 0.65
KDM4E B2RXH2 4/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
GAA P10253 3/20 0.56
MAPT P10636 3/20 0.56
HTT P42858 2/20 0.56
CFTR P13569 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
NSD2 O96028 1/20 0.51
ALPL P05186 1/20 0.51
POLB P06746 1/20 0.51
ALPI P09923 1/20 0.51
CASP6 P55212 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAOA P21397 3/20 0.50
MAOB P27338 3/20 0.50
CCR4 P51679 1/20 0.50
PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7111399 0.85 ALOX5 (0.80) ALOX5VCPMEN1KMT2AGAA
SCHEMBL23742654 0.85 VCP (0.58) ALOX5VCPKDM4EMEN1KMT2A
SCHEMBL12298086 0.82 CFTR (0.64) ALOX5VCPKDM4EMEN1KMT2A
SCHEMBL1882944 0.82 ALOX5 (0.75) ALOX5VCPMEN1KMT2AMAPT
SCHEMBL14458516 0.81 ALOX5 (0.72) ALOX5VCPKDM4EMEN1KMT2A
SCHEMBL7109033 0.79 VCP (0.76) ALOX5VCPKDM4EMEN1KMT2A
SCHEMBL3603836 0.79 MAPT (0.59) ALOX5VCPKDM4EMEN1KMT2A
SCHEMBL1821422 0.79 VCP (0.76) ALOX5VCPKDM4EMEN1KMT2A
SCHEMBL27698166 0.78 VCP (0.49) ALOX5VCPKDM4EMEN1KMT2A
SCHEMBL18029574 0.77 NPC1 (0.73) VCPKDM4EMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR ALOX5 2140/4885VCP 2712/4885KDM4E 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.